Patent · US Active

Anti-BAFFR antibody formulations

US9458240B2 · kind B2 · utility

5Cited by

0References

16Claims

0Family size

Assignee

Novartis Pharma AG · CH

Inventors

Marta Cosenza · Basel, CH
Christoph Heusser · Oberwil, CH
Julia Neugebauer · Munich, DE
Eveline Schaadt · Munich, DE
Stefanie Urlinger · Munich, DE
Maximilian Woisetschlaeger · Oberwil, CH

Key dates

Filing date	Dec 8, 2011
Grant date	Oct 4, 2016
Priority date	—
Expiry date	Dec 1, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.